Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $273,000.

  • Northwest Biotherapeutics' Share-based Compensation fell 60.15% to $273,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 67.75%. This contributed to the annual value of $3.5 million for FY2024, which is 21.60% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Share-based Compensation stood at $273,000 for Q3 2025, which was down 25.00% from $364,000 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Share-based Compensation ranged from a high of $9.8 million in Q1 2021 and a low of $273,000 during Q3 2025.
  • Moreover, its 3-year median value for Share-based Compensation was $685,000 (2024), whereas its average is $807,818.
  • The largest annual percentage gain for Northwest Biotherapeutics' Share-based Compensation in the last 5 years was 10,045.71% (2021), contrasted with its biggest fall of 96.75% (2021).
  • Northwest Biotherapeutics' Share-based Compensation (Quarterly) stood at $866,000 in 2021, then surged by 195.27% to $2.6 million in 2022, then slumped by 38.40% to $1.6 million in 2023, then tumbled by 71.17% to $454,000 in 2024, then plummeted by 60.15% to $273,000 in 2025.
  • Its Share-based Compensation stands at $273,000 for Q3 2025, versus $364,000 for Q2 2025 and $385,000 for Q1 2025.